untitled
|
|
|
- ぜんすけ みのしま
- 7 years ago
- Views:
Transcription
1
2 Cd: cr : 2MG: 2-1MG: 1- RBP:
3
4
5 WHO
6 g/l 5 g/l Peplow D, Edmonds R. 230mg/kg 2.5mg/kg 246µg/L 161µg/L Lee JS, 2005
7 µg/ µg/kg / PTWI 17-30% 0.5µg/ 0.02µg/ Puklova V et al. 2005
8 WHO 3 µg/l 0.5% 5.8% 10% PTWI 0.68% 2.06% PTWI 27.4% 29.1% Barton H, 2005
9 0.2ppm 0.25% 0.4ppm 0.4ppm 1.
10 PTWI Galal-Gorchev H.,1993
11 5.2.3
12 5.2.4 PTWI
13
14 µg/ 10 PTWI 50% 10 mg/ 10% 20µg/ Louekari K.,1992
15 % 24.5% 12.0% 8.1% 7.1%
16
17 µg/ 10 PTWI 50%
18 µg/kg/ 8 µg/kg/ PTWI 0.44µg/kg/
19
20 Cd 16,024 Cd Cd Cd Cd Mannino et al (2004)
21 8.3.1 West Midlands Sorahan and Esmen (2004)
22 ( 9-34 ) 3-15mg/m 3 Friberg (1948a, 1948b, 1950)
23 8.3.2 Cd Cd mg/m 3 0.7mg/m (de Silva and Donnan 1981)
24 8.3.2 Lauwerys (1974, 1979) 115 Cd matched case control study Cd 1-58 / 3 Cd 20 / / / 3 1
25 8.3.2 Cd (1982) 7 Cd mg/m 3 8 1mg/m 3 7 Cd 2.08 g/dl 32.6 g/l 2MG
26 8.3.2 Cd 1950 Friberg (1950) Cd (Adams 1979,.Baader 1951, Bonnell 1955, Bonnell et al 1960, de Siva and Donnan 1981, Lauwerys et al 1974, Suzuki et al 1965, Tuchiya 1967)
27 Cd (Hansen 1977) 25 2MG
28 8.3.2 Cd (Bernard 1979) MG 34 31
29 8.3.2 Cd Cd (Adams et al 1969, Bonnell 1959l, Kazantzis 1963, Suzuki et al 1965)
30 8.3.2 Cd 60 ( 58 2 ) 4-24 Cd (Elinder et al 1985) 2MG 40 Cd 2MG MG
31 8.3.2 Kawada (1993) Cd Cd 0.857mg/m mg/m 3 Cd Cd
32 MG 300 g/g cr Cd 20 g/g cr 2MG g/g cr Cd 2 g/g cr 2MG 1500 g/g cr Cd 20 g/g cr Cd (McDiarmid et al 1997)
33 8.3.2 Nicaud(1942) Ni-Cd Friberg(1950) Cd
34 8.3.2 Scott (1976) Cd Cd 3 Cd g/l
35 8.3.2 Cd 92 ( ) Cd mg/m 3 (Vorobjeva 1980)
36 8.3.2 Cd
37 8.3.2 Cd, Cd Cd g/m g/m g/m 3 (Lemen et al 1976)
38 8.3.2 Cd 5 Cd Cd mg/m mg/m g/m (Kjellstrom et al)
39 8.3.2 Cd Cd
40 8.3.2 Cd 602 Cd (Thun et al 1985) Cd SMR 584mg-day/m 3 SMR= mgday/m 3 SMR= mgday/m 3 SMR=280
41 Cd 20 Cd Cd
42 Cd Cd
43 , 031 X 61 2,
44 ,711 6,
45
46 Ca P Ca/P 1975
47 Cd µg/g cr µg/g cr. 30.0µg/g cr. 1975
48
49 Cd Ca P Ca/P Cd P P Cd Nogawa 1979a
50
51 Cd 6, ,155 7,028 13,183
52 Cd Cd Osawa 2001; Watanabe 2002 Cd Kobayashi E, 2002; Chiyoda 2003; Watanabe 2004
53 Cd Cd Cd
54 Cd Kingsbury-Clark Benedict 1971a; 1971b
55 Cd Kingsbury- Clark
56 Cd Cd
57 Cd retinol-binding protein RBP 1971; Kanai MG 1976
58 MG Cd Cd Kjellström MG MG 2MG Cd Shiroishi 1977
59 Cd Nogawa 1979b; 1982a RBP 2MG
60 MG RBP 60 Cd 2MG RBP Cd S Cd b
61 RBP 2MG 2MG RBP Cd 2MG S probit Cd 2MG RBP probit Nogawa 1979b
62 Cd RBP Cd Nogawa 1977
63 %TRP Cd sensitivity Nogawa 1980; 1981
64 MG RBP lysozyme Ccr PAH PSP Cd Nogawa 1984
65 µg/g cr. 1880µg/g cr. 2000µg/g cr. 880µg/g cr. 2MG RBP Tohyama
66 MG N-acetyl- -D-glucosaminidase NAG NAG 2MG 2MG Cd Nogawa 1983
67 Cd 141 NAG 2MG NAG 100U/g cr. 2MG 50,000µg/g cr. NAG 2MG NAG Nogawa 1986
68 Cd Aoshima Cd Cd
69 Cd 11 2MG 1MG Cd ph 2
70 MG 1mg/g cr 100mg/g cr Cd ppm Cd ppm
71 Cd Cd Cd
72 Cd
73 Nogawa (1978) Cd Cd Cd retinol binding protein (RBP)
74 ( ) Cd N 80 2 ( 2MG) 1,000 g/g cr Cd % 18.7% Kido (1987)
75 (MT) MT 97.5% 638 g/g cr 693 g/g cr) Kido (1987)
76 Cd 2MG probit linear model (Ishizaki et al., 1989) logistic linear model (Hayano et al., 1996) 2MG Cd g/g cr g/g cr
77 MT Cd g/g cr (Kido et al., 1991)
78 Nogawa (1989) Cd 50 1,850 ( ) 2MG 2
79 Kido (1993) MT logistic linear model 2.2g 2.3g
80 Hochi (1995) Nogawa N 2MG MT g MT g Cd 2g
81 MG MT 2MG MT Cd 0.34ppm (Nakashima et al., 1997)
82 Cd 74 ( ) Cd MG 1000 g/g cr 2MG 1000 g/g cr 5 Cd 5 (Kido et al., 1988)
83 , Cd 1975, 1977a, , 13, 2.5
84 ,, 33 10,,, 2-microglobulin 2MG r=0.62, r=0.57, Cd r=0.50, 1977b, Cd 0.64ppm N=85,, 1981
85 Kojima 1977, Cd , , 93 Cd 150 g/, 40 g/, Cd g/l 2MG 700 g/l, 14, 3.2
86 , ,,,,,,
87 Iwata 1992, MG , Cox, 2MG 2MG
88 ,,, 4, Cd 1300, 1960, 1973
89 , 1979, , 1985, ,, Cd, 60 50,,, g/g creatinine cr.
90 MG, 70 50,,, 70 1,000 g/g cr. 2MG,
91 , 1985,,, MG 1,000 g/g cr.,, 2MG,, 2MG, 1MG,,
92 Cd 6.6, 11.2 g/g cr., 1MG metallothionein, Tohyama et al., 1986; 1988
93 Iwata 1993, MG Cd , 1981, Cd g/ g/ Cd 8.5 g/g cr. 6.0 g/g cr.
94 , 2MG 40 2MG 1,000 g/g cr. 1.8, Cd, 1998, , Cd, Cd 14,, HCO3-, 9,,
95 Iwata 1991a, 1991b, Arisawa , , 2MG 1,000 g/g cr. SMR [CI] , CI , Cox, 2MG,, 2MG Iwata et al., 1991b
96 , 2MG 1,000 g/g cr. SMR CI , CI 7-103, SMR 101, 95% CI , SMR 126, 95% CI Arisawa et al., 2001, 2MG 1,000 g/g cr., 1,000 g/g cr. SMR % CI , 66 95% CI 49-87, 90 95% CI
97 Cd, 4.4, 4.2, 2.9, 0.2, 0.2, 0.1, 0, 7 0, 1979
98 Kawada, , Cd N-acetyl- -D-glucosaminidase NAG Cd 1.59, 1.48 g/g cr. Cd, Cd NAG r=0.20, p<0.01 2MG
99 Nakadaira 2003, Cd Cd 2.69, 4.68 g/g cr. 1.08, 1.69 g/g cr., 2MG 1,000 g/g cr.
100 ,000 30,000 4,000 13,
101
102 / / / /
103 / Cd /L / 1996
104 / 2001 Horiguchi(2005) / /Kg / (7 /Kg) 21.1 / g/ 1997
105 WHO, 1992; Goyer and Clarkson, 2001; Thevenod, 2003
106 µg/ µg/ 10 Thun et al., mg Nogawa et al., µg/ Satarug et al., 2003
107 9 2 2 D WHO, 1992 Honda et al., 2003 JMETS Horiguchi et al.
108 9 2 3 Goyer and Clarkson, 2001 WHO, 1992
109 9 2 4 WHO, 1992 Houtman, 1993; Nishijo et al., Järup, 1998; Goyer and Clarkson, 2001;, 2002
110 9 2 5 Goyer and Clarkson, 2001
111 9 2 6, 2002 in vitro in vivo (Johnson et al. 2003)
112 9 2 7, IARC A Verougstraete et al, 2003
113 9 2 7 Sorahan and Lancashire, 1997; Verougstraete et al, , 2002; Verougstraete et al, 2003 Goyer and Clarkson, 2001
114 9 2 8 N- - -D- 1 WHO, 1992; Goyer and Clarkson, 2001
115 In animals 150 µg/g, µg/g, µg/g Brzoska et al., 2003, 2004
116 In humans µg/g µg/g WHO, 1992; Goyer and Clarkson, 2001;, JECFA PTWI 7 µg/kg / 50 µg/g, 2003; Horiguchi et al., µg/g 50 µg/g 3.9 Lyon et al., 1999
117 Suwazono et al (2000) 2 Cd 4 1,105 1,608 Cd Cd Cd Cd Cd 2MG NAG Cd Cd 2MG NAG Cd
118 Ezaki et al (2003) 10 Cd 10,753 1,000 / Cd 1MG 2MG 1MG 2MG Cd 1MG 2MG
119 Ezaki et al (2003) 10 Cd 10,753 1,000 / Cd 1MG 2MG 1MG 2MG Cd 1MG 2MG Suwazono et al (2000) 1 Ezaki et al (2003)
120 Cd Cd Ezaki et al (2003) Cd MG 2MG Cd PTWI Cd PTWI Cd
121 Diamond et al (2003) Cd 15 Cd Cd Cd
122 9.4.2 Horiguchi et al (2004) 5 Cd 1,381 Cd MG 2MG Cd Cd provisional tolerable weekly intake; PTWI Cd Horiguchi et al. 2005)
123 Cd Cd Cd (Kjellström 1977a)
124 EU Cd Cd Cd 5.5 g Cd/l 5.4 g Cd/g cr 2 g Cd/g cr 4 g Cd/g cr 10 g Cd/g cr (Roels et al 1993)
125 Cd 45 Cd 2MG RBP Cd Cd 300 mg/m Thun et al., 1989)
126 Cd
127 1
128
129 WHO 30mg/ l 300mg/ l
130
131 94-98% 2% 24
132 15-20%
133 Third National Health and Nutrition Examination Survey (NHANES III)
134 Third National Health and Nutrition Examination Survey (NHANES III) (Brody et al. 1994),
135 (Brody et al. 1994) g/g cr.) 2MG ( g/g cr.)
136 10 10,
137 1MG 2MG 3 1MG 2MG
138 1MG 2MG ( R=0.272 R=0.202) R=0.280 R= MG 2MG
139 1MG 2MG
140
レイアウト 1
1 3 6 7 8 3 6 7 8 g mg 6 1 16 16 18 16 13 138 13 16 1 11 8 78 8 17 9 9 g mg 18 13 1 1 1 99 6 3 36 3 3 8 1 18 18 18 16 16 1 1 g mg 1 1 13 13 1 11 11 g mg 8 6 g 1 g mg 93 38 9 93 8 8 176 1 1 1 1 11 18
% %
4 8 4 5 414.5 172.1 41.5% 39.8 10% 17 186.4 70.8 4 9 10 11 3 1-1 - 2-2 - - 3 - 10% - 4 - 4060% 5560% 60% 40% 3040 1520 1015 411 7 4 11 610 7080 5060 100 3040 13-5 - 1015 4045 3.04.0 5.06.0 1.52.0 1.01.5
,977 t 157,977 t mg l mg l BOD 9398 % OH = cm 3 / sec 11 = cm 3 / sec OH = /
1 9625 2219 CAS 75569 1, 2-1, 2- H 2 C CH CH 3 C 3 H 6 O 58.08 1 99 % 1. 2 2, 3-112.13 2, 3 34.23-37 449 2.8-37 % 2 d 0 4 0.859 4 d 20 0.8304 2 2, 4 2.00 = 1 53.33 kpa 400 mmhg18 59.33 kpa 445 mmhg20 5
bc0710_010_015.indd
Case Study.01 Case Study.02 30 Case Study.05 Case Study.03 Case Study.04 Case Study.06 Case Study.07 Case Study.08 Case Study.21 Case Study.22 Case Study.24 Case Study.23 Case Study.25 Case Study.26
2
1 2 3 4 5 6 7 8 9 10 11 12 13 14 10mSv 15 16 17 4.46 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 3.8 2.07 2.91 1.37 2.3 1.31 1.84 1.56 1.2 1.33 2.03 0.5 1000 4000mSv 1000 4000mSv Preston et al. Radiat Res 168: 1 64,
14 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 20 0 0 0 0 0 0 0 0 0 0 0 0 21 0 0 0 0 0 0 0 0 0 0 0 0 22 0 0 0 0 0 0 0 0 0 0 0 0 23 0 0 0 0 0 0 0 0 0 0 0 0 24 0 0 0 0 0 0 0 0 0 0 0 0 25 0 0 0 0 0 0 0 0 0
取扱説明書 ［F-02F］
F-02F 4. 2 3 4 5 6 7 8 9 0 2 3 4 5 6 7 8 a b c d a b c d a b cd 9 e a b c d e 20 2 22 ab a b 23 a b 24 c d e 25 26 o a b c p q r s t u v w d h i j k l e f g d m n a b c d e f g h i j k l m n x 27 o
- 108 -
3-107- - 108 - 3.1 3.1.1 3.1.2 3.1.2.1 5 LD50 LC50 ATE 3.1.1 1 2 3 4 5 (mg kg ) 5 50 300 2000 5000 a (mg kg ) 50 200 1000 2000 a (ppm) 100 500 2500 5000 a b mg 0.5 2.0 10 20 a b c d 0.05 0.5 1.0 5 (mg
,309 t 22,069 t 7,240 t µg/l µg/l < ,431-70, , , mg/l m
1 20019 1527 CAS 1317368 1230 PbO 223.20 1 99 1. 2 888 2 9.53 0.017 g/l 20 3 3 2 2. 10 29,309 t 22,069 t 7,240 t 4 1 3. 1 2 3.5 6 1 µg/l 9.1-24 2 µg/l < 43 6 27,431-70,000 4.5-1,300 13.4-17 31.7 0.48-3,459
12 40 7 1995 9 11 12 5 10 5 8 9 6 10 7 19 20 100 1 2 3 4 31 1956 5 28 1953 12 54 17 32 1957 40 1965 5 40 1965 7 26 5 5 11 1999 2,263 40 895 11 1999 690 352 7 1995 12 11,152 10,353 799 28 1953 1 6 31
環境基準項目等の設定根拠等
7440-43-9 Cd 112.4 ph (CdCl 2 ) (CdO) (CdSO 4 ) 80 8.6 4.1 6.95 4.7 75.5g/100ml (0) 2,471,566t( ) 12 251kg( ) 3,916,204kg( ) (1) 0.01mg/l 0.0310g/l 0.01mg/l 60 (2) 0.003mg/l 0.005mg/l 0.005mg/l 0.01mg/l
五訂増補日本食品標準成分表（本表） 肉類
Minerals Vitamins Fatty acids Item No. Food and description 1 2 6 12 kcal kj g mg µg mg µg mg µg mg g mg gg Water Protein Lipid Carbohydrate Sodium Potassium Calcium Magnesium Phosphorus Zinc Manganese
speax326KCL
115V 200V 10 100 10 100m 1 2 3 4 5 6 7 8 9 0 1 2 1 2 3 4 5 1 2 1 3 2 4 5 6 7 8 9 1 2 3 4 5 6 1 1 2 3 4 5 6 7 2 1 2 3 4 5 1 2 3 4 1 2 3 4 1 2 3 4 1 2 1 2 1 2 3 4 1 2 3 1 2 3 4 1 2 3 1 2 3
3, ,104 t mg/l 30 mg/l BOD mg 14 C 8, /kg 11 8, 1 11 OH = cm 3 / sec 11 OH /cm ppm
3, 3-1 200019 4800 CAS 91941 1138 3, 3-4, 4 - -3, 3 - H 2 N Cl Cl NH 2 C 12 H 10 C l2 N 2 253.13 1 95 1. 2 3, 4 132-133 402 5 >200 5 700kg/m 3 5 8.73 = 1 5.610-8 kpa 4.210-7 mmhg20 4 6 log Pow3.51 3.57
L- 19 L L- L-
0131001 15 1 31 49 35 145 14 5 19 4 23 15 3 10 7 15 634 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 L- 19 L- 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49
untitled
NPO 2006( ) 11 14 ( ) (2006/12/3) 1 50% % - - (CO+H2) ( ) 6 44 1) --- 2) ( CO H2 ) 2 3 3 90 3 3 2 3 2004 ( ) 1 1 4 1 20% 5 ( ) ( ) 2 6 MAWERA ) MAWERA ( ) ( ) 7 6MW -- 175kW 8 ( ) 900 10 2 2 2 9 -- - 10
Taro9-医薬品目次２０１２－１.PDF
5 0.1% 11 250mg 10 20mg 10 5ml 19 0.05% 13 1.25mg 10 1%5ml 19 10mg 10 0.2%100ml 18 25%50ml 9 2mg 17 5%250ml 9 20%25g 20 500 g 11 4 10g 20 Cap150mg 1 200mg 0 Cap90mg 5 20mg 10 10% 5 18 10mg 10 3%30g 20
: : 2001227 : 2
: : 2001227 : 2 mg/100gmg/100g mg/100g 3 10/102006 12/05 2/19, 2007 Zn 63 98 4 10% 5 Ramesh et al. 2004 6 Connoly et al. 2002 A IRT 7 8 2.11mg/100g143%56% 9 10 Alaria praelonga 11 2 12 13 14 15 16 1 1
untitled
b 0 1PPm 10PPm 100PPm 1000PPm 10000PPm 0.0001% 0.001% 0.01% 0.1% 1% 10% 1PPm 10PPm 100PPm 1000PPm 10000PPm 0.0001% 0.001% 0.01% 0.1% 1% 10% 1PPm 10PPm 100PPm 1000PPm 10000PPm 0.0001% 0.001% 0.01%
14 4 12 10 8 6 3 2 4 2 1 0 0 100200300400500600 100200300400500600700 0 0 100200300400500600 100200300400500600700 (ppm) (ppm) 7 4 6 5 4 3 3 2 2 1 1 0 0 100200300400500600 100200300400500600700 0 0 100200300400500600
I
I II 1 2 3 4 5 6 7 8 9 10 11 Rp.1) 50mg 3 3 14 Rp.2) 2.5mg 2 14 Rp.1) 2.5mg 3 2 2:1 14 Rp.) 15g 1 3 28 Rp.2) 50 600mg 1 2 28 12 Rp.1) CR 20mg 1 1 1 14 Rp.2) R 200 1 2 14 Rp.3) 3 1 3 14 Rp.1) 2.5mg 0.4
【知事入れ版】270804_鳥取県人口ビジョン素案
7 6 5 4 3 2 1 65 1564 14 192 193 194 195 196 197 198 199 2 21 22 23 24 1.65 1,4 1.6 1,2 1.55 1, 1.45 6 1.5 8 1.4 4 1.35 1.3 2 27 28 29 21 211 212 213 214 6 5 4 3 2 1 213 218 223 228 233 238 243 248 253
10 2 2 10 6.5 78 1 65 / 30 / - 2 -
- 1 - 10 2 2 10 6.5 78 1 65 / 30 / - 2 - 3 3 30 8 4 8 6 11 14 45 14 7 8 1-3 - 4 1 () 20 4 9 4 9 3 9 4 PR 4 3-4 - - 5 - PR 15 4 PR 7 8 4 9 10-6 - 9 10 9 10 4 9 10 3 9 10 9 9 9 10 PR 1-7 - PR - 8 - 30 100-9
五訂増補日本食品標準成分表（本表） 果実類
Cryptoxanthin Minerals Vitamins Fatty acids Item No. Food and description 1 2 6 12 kcal kj g mg µg mg µg mg µg mg g mg gg Sodium Potassium Calcium Magnesium Phosphorus Zinc Manganese Retinol Item No. Food
<4D F736F F D B BA908593B98AC782AB82E593E082CC88C091538AC7979D82C98AD682B782E992868AD495F18D908F912E646F63>
12 62 1800 14 3 11 14 4 14 4 30 ... 1... 1... 1... 2... 5... 6... 7... 10... 13... 18... 19 21 22 24 27 28 31 32 33... 34... 35... 37 2 1,650mm () H=2,500W=2,000 460m 750m 500m 42.1m 1.15m () 100% 80%
t 492 t mg/l 30 mg/l BOD 95 OH = cm 3 / sec 25 8 OH /cm 3 12 = ph ph
2-1 200169 2740 CAS 110-49-6 1103 2- O H 3 C C O CH 2 CH 2 O CH 3 C 5 H 10 O 3 118.13 200168 2-1 99 2-1. 2 2, 3-65 2, 3 144145 45 o.c. 3 392 3 1.512.3 d19 1.009 2 4.07 = 1 30 Pa 0.23 mmhg20 2 4 log Pow0.10
1 3 2 4 1983 2 1979 04 1 03 GDP 9.1% 1 GDP 1,000 04 3 10 04 01 12 WTO WTO 4 3 3 1979 1973 1974 1978 1978 11 1979 1982 1982 1984 1988 1989 1989 1998 SEPA 5 1979 1989 3 1,000 9 SEPA 10 1982 6 5 5 6 1993
040202PC用.doc
15 48 15 8 25 15 1321 15 8 25 0825002 15 8 25 6 8 15 2 18 15 6 27 2 15 3 13 28 35 (1) 51 198 7 (2) 3 6 1 100g (1) 1 (1) 1 2 1 astaxanthin;3,3 -dihydroxy-, -carotene-4,4 -dione (2) 1 2 C40H52O4 596.86 97.0
,161 t 9,753 t 2,408 t LC 50 mg/ L EC 50 mg/l * 5 : Selenastrum 6772-h, Sb 2 O 3, : capricornutum 6 3 Selenastrum h, Sb
1 20017 1543 CAS 1309644 125 Sb 2 O 3 291.52 1 99 1. 2 655 1,425 2 2 2 3 5.2 5.67 2 2 2. 10 12,161 t 9,753 t 2,408 t 4 3. 1 2 3 4. LC 50 mg/ L EC 50 mg/l * 5 : Selenastrum 6772-h, Sb 2 O 3, : capricornutum
取扱説明書 ［F-12C］
F-12C 11.7 1 2 3 4 5 6 7 8 9 10 11 12 13 14 a bc b c d d a 15 a b cd e a b c d e 16 17 18 de a b 19 c d 20 a b a b c a d e k l m e b c d f g h i j p q r c d e f g h i j n o s 21 k l m n o p q r s a X
Microsoft Word - 表紙資料２－４
(1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)
( 50kg 26 (22
2 ( 50kg 26 (22 50 3 ( 50 WHO (27 101 1967 1968 1970 1970 Cd, Cu, As 1991 2002 1968 1970 Cu, Cd, As) 1975 1984 Hg, Cd 1986 1991 1992 1994 5 1994 1999 1999 2002 (2003 1975 1980 1985 1990 1995 1998 (26
薬局におけるインシデント事例の集計･分析結果
13 11 14 31 13 11 14 31 13 11 14 31 10 13 13 e-mail 18 4,000 13 14 H13.4.1 11.17 11.18 H14.3.31 13 14 31-1- 600 400 (18.4 17.7 17.0 16.0 15.2 8.2 1.0 2 11 10 12 15 3 1015203040 69.5 7.8 22.7 4 (42.5) 34.3
untitled
20073-1- 3 4 5 9 12 14 17-2- 3,700ha 30,000t -3- 1t 70 50 40 C/N -4- 20011228 C/N 13 2001 2cm 1t 60 70 60-5- 70 1t -6- 2003131 ph EC T-C T-N C/N P2O5 K2O CaO MgO HO 2 ms % % % % % % % 8.52 0.64 74.9 44.9
1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)
2010.1.13 1) 4) 2 18 1) 1 2 3 4 2) 1 2 85 3 3) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer 4 5 6 4 7 2 5 (PPI) 1 2 PPI 2 3 2 3 3 3 3 PPI 3 1 ph 4 5 1) 5)
a
1 a b c a b a 2 kg ms/cm 20 40 60 80 20 40 60 80 20 40 60 80 15 18 22 25 11 14 24 25 9 24 31 31 3? 32 32 26 33 33 33 33 33 30 29 30 14?? 21 28 9 16 22 26 11 16 22 24 11 14 17 15 10 11 22 25 7 12 26 30
医薬品リスク管理計画書
2.5 mg 3.75 mg 5 mg 20mg RMP 2.5 mg 3.75 mg 5 mg 20mg 87339 28 6 1.1 4 8 10 5 8 10 5 TTP 9 梗 6 TIA 11 6 1.2 11 CABG 12 12 13 13 15 2.5mg 15 2. 16 3. 16 4. 19 19 19 18 RMP 28 6 3 5 1 27 8 25 26 3 24 87339
12-7 12-7 12-7 12-7 12-8 12-10 12-10 12-10 12-11 12-12 12-12 12-14 12-15 12-17 12-18 10 12-19 12-20 12-20 12-21 12-22 12-22 12-23 12-25 12-26 12-26 12-29 12-30 12-30 12-31 12-33 12-34 12-3 12-35 12-36
Contents P.1 0. JGPSSIVer P2 1. P3 2. P P P46 4. JGP 4-1. P P P P P P P27 8. P P
version 5.10 JGPSSI Ver.4.20/V 20128 JGPSSI JGPSSI Ver.4.20 Contents P.1 0. JGPSSIVer. 4.11 P2 1. P3 2. P3 3. 3-1. P4 3-2. P46 4. JGP 4-1. P7 4-2. P713 5. P1420 6. P2126 7. 6-1 P27 6-2 P27 6-3 P27 8. P2838
PAH ; XAD-2 ( XAD-2) PAH - LH-20 (HPLC) (SE-54 SE-52) ; -C18 HPLC PAH 1.3 PAH PAH PAH ( ) ( ) (, ) ( ) PAH : - bitumen ; - ; - ; - ; - ; - environment
No.202 Environmental Health Criteria No.202 (PAH) Selected Non-heterocyclic Polycyclic Aromatic Hydrocarbons ( 883 1998 ) 1. 1.1 (PAH) PAH PAH PAH 33 (31 PAH 2 ) ( 1) 8 10 PAH PAH 10-15 ; 1.2 ' ' 2 PAH
水銀に関する水俣条約対応検討小委員会
EU 4 1 0.0005 % 4 1 0.002 % * 21 1 0.0005%0.002%0.004% Hg Cd Pb21 3 EU EU RoHS 76 77 EEE 2006 7 EU EEE 78 76 Restriction of Hazardous Substances Directive:2011/65/EU2011. 7.21 2013. 1. 7 http://eur-lex.europa.eu/lexuriserv/lexuriserv.do?uri=consleg:2011l0065:20130107:en:pdf
17. (1) 18. (1) 19. (1) 20. (1) 21. (1) (3) 22. (1) (3) 23. (1) (3) (1) (3) 25. (1) (3) 26. (1) 27. (1) (3) 28. (1) 29. (1) 2
1. (1) 2. 2 (1) 4. (1) 5. (1) 6. (1) 7. (1) 8. (1) 9. (1) 10. (1) 11. (1) 12. (1) 13. (1) 14. (1) 15. (1) (3) 16. (1) 1 17. (1) 18. (1) 19. (1) 20. (1) 21. (1) (3) 22. (1) (3) 23. (1) (3) 24. 1 (1) (3)
1. PVC PVC DEHP DEHP PVC PVC PVC PVC , PVC , ,596 PVC ,472 16% PVC
(2- ) 2003 5 1. PVC PVC DEHP DEHP 2. 2.1 PVC PVC PVC 1930 1941 PVC 1943 37,000 1944 116 200500 PVC 1950 1,493 2000 268 2,596 PVC 2000 1,472 16% PVC 1948 190 2000 36 470 8% 80% DEHP 60% 50% DEHP PVC % 2.2
Contents 1 4 Section Column Section
Contents 1 4 Section1 7 8 16 23 34 40 Column Section2 47 48 58 64 70 Section3 75 76 82 88 Interview Interview 94 96 Prologue Prologue Section 1 1 8 9 Section 1 10 1 19.8 19.1 17.4 14.6 16.0 16.9 48.7
![かんたん操作ガイド[arrows M02]](/thumbs/39/20071242.jpg "かんたん操作ガイド[arrows M02]")
![かんたん操作ガイド[arrows RM02]](/thumbs/39/20475147.jpg "かんたん操作ガイド[arrows RM02]")
![かんたん操作ガイド[arrows M03]](/thumbs/42/22941141.jpg "かんたん操作ガイド[arrows M03]")
98-02.PDF
1 982 2207 CAS 67630 2- H 3 C H 3 C CH OH C 3 H 8 O 60.10 1 99.9 % n- 1. 2-88.5 3 82.5 3 11.7c.c. 455 4 212 d 20 4 0.78505 3 2.1 = 1 4 4.4 kpa 33 mmhg20 4 log Pow0.05 0.07 5 m/z45, 1.0 43 0.19 27 0.17
CAS O C O * DOP* DEHP 2- C O O * n- C 24 H 38 O CH 2 CH 2 CH 2 CH 3 CH (CH 2 ) % 2- A BHT , 4
2-1 9628 31307 CAS 117817 2- O C O * DOP* DEHP 2- C O O * n- C 24 H 38 O 4 390.56 CH 2 CH 2 CH 2 CH 3 CH (CH 2 ) 3 1 99 % 2- ABHT 1. 2-55 3 3, 4 386 171 350 6 0.1 % d 20 4 0.9861 4 13.48 0.30410-4 Pa 2.2810-7
温泉の化学 １
H O 1,003 516 149 124 2,237 1974 90 110 1km 2,400 ( 100 Mg 200 (98 ) 43,665 mg 38,695 mg 19,000 mg 2000 2000 Na-Ca-Cl 806 1970 1989 10 1991 4 ph 1 981 10,000 1993... (^^; (SO_4^{2-}) " " 1973-1987 1970
香南市・香美市のニラ
ROTTLER Chinese chives Alliaceae Allium 133 33 33 33 133 41 36 12 1 ha2 3 JA 4 1 H17 23 2010 4 JA 22 40,000~50,000 10a 4 100 5 120 6~8 120~150 20,000~30,000 10a 810 30 911 47 40 123 50 10a kg 4,000kg
（個別のテーマ） 薬剤に関連した医療事故
- 67 - III - 68 - - 69 - III - 70 - - 71 - III - 72 - - 73 - III - 74 - - 75 - III - 76 - - 77 - III - 78 - - 79 - III - 80 - - 81 - III - 82 - - 83 - III - 84 - - 85 - - 86 - III - 87 - III - 88 - - 89
（個別のテーマ） 放射線検査に関連した医療事故
- 131 - III - 132 - - 133 - III - 134 - - 135 - III - 136 - - 137 - III - 138 - - 139 - III - 140 - - 141 - III - 142 - - 143 - III - 144 - - 145 - III - 146 - - 147 - III - 148 - - 149 - III - 150 - -
2006
2006.11.25 92 1869 H 92 U 19 1895 X 1896. 20 92 X X 1 ev DNA ev DNA DNA 300 28 JCO 1999 9 JCO DNA 1934 66 X X 15 40 2 2.4 3 BEIR-VII 0.01 50 50 0.5 100 0.5 5000 30 1.6 2.25 2.25 1000 0.2 0.1 2000 10 245
O157 6/23 7/4 6 25 1000 117,050 6 14:00~15:30 1 2 22 22 14:30~15:30 8 12 1 5 20 6 20 10 11 30 9 10 6 1 30 6 6 0 30 6 19 0 3 27 6 20 0 50 1 2 6 4 61 1 6 5 1 2 1 2 6 19 6 4 15 6 1 6 30 6 24 30 59
サービス付き高齢者向け住宅賠償責任保険.indd
1 2 1 CASE 1 1 2 CASE 2 CASE 3 CASE 4 3 CASE 5 4 3 4 5 6 2 CASE 1 CASE 2 CASE 3 7 8 3 9 10 CASE 1 CASE 2 CASE 3 CASE 4 11 12 13 14 1 1 2 FAX:03-3375-8470 2 3 3 4 4 3 15 16 FAX:03-3375-8470 1 2 0570-022808
製品案内 価格表 2014/4/1
4 (17) 3 43 5/20370/ 231(504,150) 11 12 10 14-16 10 3 100 17 100kg 5-6 3 13 3 18 18 # # # # #$$ %&$ ' ()* +,-% ' #). +,-%'% / ' # # #$ %&&&'( %)* +'(#$ #$ %&&&'( ++,-). +'(#$ #$ /'( + /0)- +'(#$ %&&&'(
16 41 17 22 12 10
1914 11 1897 99 16 41 17 22 12 10 11 10 18 11 2618 12 22 28 15 1912 13 191516 2,930 1914 5,100 43 1.25 11 14 25 34364511 7.54 191420 434849 72 191536 1739 17 1918 1915 60 1913 70 10 10 10 99.5 1898 19034.17.6
３．ごみの減量方法.PDF
- 7 - - 8 - - 9 - - 10 - - 11 - - 12 - ( 100 ( 100 - 13-123,550,846 111,195,762 92,663,135 ( 12 25 37 49.2 16 33 49 65.6 15 30 44 59.0 2.5kg) ( 5kg) ( 7.5kg) ( k ( 123,550,846 111,195,762 92,663,135 (
橡三酸化二アンチモン.PDF
1 2001 7 1 543( ) CAS 1309 64 4 1 25 ( ) Sb 2 O 3 291.52 1) 99 1. 2) 655 3) 1,425 3) ( ) 2) ( ) 2) ( ) 2) 5.2 ( ) 5.67 ( ) 3) 2) 2. 10 12,161 t ( 9,753 t 2,408 t) 4 2 1) 3. 1) 2) 3) 4. Selenastrum capricornutum
1 I ( )
1 I. 3 1. 4 2. 6 3. 7 4. 8 4.1 8 4.2 ( ) 9 4.3 13 4.4 16 4.5 17 5. 19 5.1 20 5.2 25 5.3 33 6. 37 6.1 37 6.2 41 6.3 44 7. 46 7.1 46 7.2 47 II. 48 A 50 1 50 2 51 3 56 4 59 60 B 61 1 61 2 62 3 65 4 67 68
橡96-07.PDF
1 967 2482 CAS 50000 CH 2 O 30.03 2952% 12.5 % 1. 2) -92 2) -19.5 2) 5085 3) 424 3) 7.073.0% 4) 20 d 4 0.815 5) 1.03 ( = 1) 5) 1.33 kpa (10 mmhg) (-88.0) 2) log Pow0.35 ( ) 6) 0.35 ( ) 7) 1) m/z 29 ( 1.0
24,828,330 Contents 9,931,332 8,223,840 3,436,978 9,931,332 7,674,406 3,413,724 2,985,287 1
24,828,330 Contents 9,931,332 8,223,840 3,436,978 9,931,332 7,674,406 3,413,724 2,985,287 1 2 3 1Chapter 138 4 5 Case Study 1 Case Study 2 6 Case Study 4 7 Case Study 3 9 Case Study 6 Case Study 5 8 10
化学物質の環境リスク初期評価（平成９～１２年度）結果[39物質]
![化学物質の環境リスク初期評価（平成９～１２年度）結果[39物質]](/thumbs/39/20157433.jpg "化学物質の環境リスク初期評価（平成９～１２年度）結果[39物質]")
1,3-1,3- (1) 1,3-1,3- - CAS 542-75-6 C 3 H 4 Cl 2 110.97 2 1) -84 2) 108 2,3) 112 (trans-) 4) 104 (cis-) 4) 1.225 (20 ) 2) 5.2 kpa (39 mmhg) (25 ) 2) 4.5 kpa (34 mmhg) (25 ) 4) 5.7 kpa (43 mmhg) (25 )
橡96-01.PDF
1 961 31 CAS 71432 C 6 H 6 78.11 1) 99 % 1. 5.5 2) 80.1 2) -11 3) 293563 3) 1.48.0% 3) d 20 0.8786 4) 2.77 ( = 1) 4) 4 13.33 kpa (100 mmhg) (26.9) 2) log Pow2.13 ( ) 5) 2.14 ( ) 6) m/z78 ( 1.0 )77 ( 0.20
3章 有害性の同定
3. DE DE 3.1. 3.1.1. Waxweiler 1973 8 1940 1 1967 7 1 2,743 1,143 1967 7 1 438 433 108 112 Ahlman 1991 19541973 3 597 19541986 102 16 10 4.3 6.9 19541960 5 1.7 DE 3 DE PAH 1960 1980 BaP 20ng/m 3 CONO X